California Clinical
Trials By City

Beverly Hills California Clinical Trials

A Phase 3 Safety and Efficacy Study of Fovista™ (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista™ administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
Status: Recruiting Start Date: August 2013 Completion Date: 
Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
The purpose of this research study is to see how ETC-1002 is tolerated in the body, to measure the amount of ETC-1002 in the blood, and to determine how ETC-1002 affects the [more...]  level of LDL-cholesterol (bad cholesterol) and other markers of health and disease in blood and urine in patients with elevated LDL-cholesterol with or without statin intolerance.
Status: Recruiting Start Date: September 2013 Completion Date: December 2014
A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
This study is designed to demonstrate the non-inferior antiviral activity of DTG/ABC/3TC fixed dose combination (FDC) once daily (OD) compared to atazanavir plus ritonavir (ATV+RTV) and tenofovir disoproxil fumarate/emtricitabine fixed dose combination (TDF/FTC FDC) OD in HIV-1 infected, ART-naïve [more...]  women over 48 weeks. This study will also characterize the safety and tolerability of DTG/ABC/3TC FDC compared to ATV+RTV+TDF/FTC FDC. Sufficient number of subjects will be screened in order to ensure a total of approximately 474 subjects will be randomized (237 in each study arm)
Status: Recruiting Start Date: August 2013 Completion Date: March 2018
Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma
A prospective, randomized, open label, multi-center, parallel group, 3-arm phase III study comparing the efficacy and safety of both, LGX818 plus MEK162 and LGX818 monotherapy, as compared to vemurafenib in patients with locally advanced unresectable or metastatic melanoma with [more...]  BRAF V600 mutation. A total of approximately 900 patients will be randomized 1:1:1 to one of 3 treatment arms: 1) LGX818 plus MEK162 (denoted as Combination arm), 2) LGX818 monotherapy (denoted as LGX818 arm), 3) vemurafenib.
Status: Recruiting Start Date: September 2013 Completion Date: June 2017
Induction, STabilization, Adherence and Retention Trial (ISTART) of OX219 Buprenorphine/Naloxone
The purpose of this study is to assess treatment efficacy and adherence of OX219(Buprenorphine/Naloxone) versus SUBOXONE Film (Buprenorphine/Naloxone)and to explore switching between treatments.
Status: Recruiting Start Date: July 2013 Completion Date: March 2014
Study of Two Doses of MK-3475 Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010)
This study will compare two doses of MK-3475 versus docetaxel in participants with non-small cell lung cancer (NSCLC) who have experienced disease progression after platinum-containing systemic therapy. Participants will be assigned randomly to receive either Low Dose or High [more...]  Dose MK-3475 every three weeks (Q3W), or docetaxel at 75 mg/m^2 Q3W. This study will use an adaptive trial design so that the total number of participants randomized will depend upon demonstration of sufficient objective responses at interim analysis. If the MK-3475 Low Dose arm is closed, participants may receive MK-3475 High Dose therapy.
Status: Recruiting Start Date: August 2013 Completion Date: January 2020
A Study of Vismodegib With Surgery in Patients With Previously Untreated Basal Cell Carcinoma
This randomized, double-blind, placebo-controlled study will assess the efficacy and safety of vismodegib with surgery in patients with basal cell carcinoma. Patients will be randomized to receive oral daily doses of vismodegib 150 mg or matching placebo. The [more...]  anticipated time on study drug treatment is 12 weeks.
Status: Recruiting Start Date: June 2013 Completion Date: July 2015
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
The objectives of this study is - To evaluate the efficacy of PRC-4016 by assessment of the percentage change in blood lipids and lipoprotein parameters from baseline after 12 weeks of treatment. [more...]  - To evaluate the safety of PRC-4016 as assessed by adverse events and other safety parameters
Status: Recruiting Start Date: July 2013 Completion Date: October 2014
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
This is a three-arm study to evaluate the safety and efficacy of two dosing schedules of MK-3475 compared to ipilimumab for the treatment of ipilimumab-naïve participants with unresectable or metastatic melanoma.
Status: Recruiting Start Date: August 2013 Completion Date: July 2016
Medical Arm of the Interagency Registry for Mechanically Assisted Circulatory Support
MedaMACS is a prospective, observational study of ambulatory patients with advanced heart failure. The study enrolls patients who have not yet received a Left Ventricular Assist Device (LVAD) but who receive their care at a hospital with a Joint Commission certified [more...]  mechanical circulatory support program. MedaMACS is funded through the Interagency for Mechanically Assisted Circulatory Support (INTERMACS) NHLBI Contract.
Status: Recruiting Start Date: April 2013 Completion Date: November 2015
Scar Prevention Using Fractional Carbon Dioxide Laser Treatment
In this study the investigators intend to determine the impact of fractional CO2 laser treatment on the edges of a fresh wound during surgical area closure on thin skin (e.g. face, hands, arms, thorax, etc.) and on thick skin (abdominoplasty procedure) on scar [more...]  formation. The investigators will also evaluate the effect of shallow fractional laser treatment versus deep parameters settings. If effective treatments could be performed at time of surgery, this would result in both time and cost saving to the patient and to the healthcare system and will improve patient's self-image post surgeries.
Status: Recruiting Start Date: January 2013 Completion Date: 
Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
The primary objective of this study is to evaluate the effect of the elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single-tablet regimen (STR) on renal parameters at Week 24. To measure the proportion of subjects achieving virologic response of HIV-1 RNA < [more...]  50 copies/mL.
Status: Recruiting Start Date: March 2013 Completion Date: December 2015
Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects
The purpose of this study is to evaluate the non-inferiority of switching to a TAF-Containing Combination single tablet regimen (STR) relative to maintaining TDF-containing combination regimens in virologically-suppressed HIV-1 positive subjects as determined by having HIV-1 RNA < 50 [more...]  copies/mL at Week 48 following the switch.
Status: Recruiting Start Date: March 2013 Completion Date: July 2015
Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis
This is a Multicenter, randomized, double-blind study in subjects with moderate to severe non-radiographic Axial Spondyloarthritis. There is a 28-week open-label period followed by a 40-week double-blind, placebo-controlled period for subjects who meet the randomization criteria. Subjects who [more...]  flare during the double-blind period will have an opportunity to receive at least 12-weeks of rescue therapy.
Status: Recruiting Start Date: April 2013 Completion Date: May 2017
A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the Cryo-Touch IV Device
myoscience Inc. (Redwood City, CA) has developed a device for a novel, minimally invasive facial rejuvenation procedure designed to soften hyperdynamic facial lines. The myoscience Cryo-Touch IV device uses well-established principles of cryobiology to cause localized reduction in [more...]  muscle activity resulting in a reversible reduction in facial animation and the appearance of facial lines. The device operates on well-established cryobiology principles; that localized exposure to controlled low temperature conditions can alter tissue function. The therapy treats targeted motor nerves with low temperatures via a cold probe in the form of an assembly of small diameter needles, creating a highly localized treatment zone around the probe. The thermal algorithm is designed to produce a reversible loss of nerve conduction resulting in a temporary decrease in muscle contractility. Prior studies of Cryo-Touch, Cryo-Touch II and Cryo-Touch III have provided strong evidence of effectiveness and safety for applications in this indication. The goal of the study described herein is to show the safety and effectiveness of this approach using the Cryo-Touch IV device.
Status: Recruiting Start Date: January 2013 Completion Date: October 2013
Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults
The purpose of this study is to evaluate the efficacy of a single-tablet regimen (STR)containing elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) versus a STR containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) in HIV-1 positive, antiretroviral treatment naïve adult subjects as determined [more...]  by the achievement of HIV-1 RNA < 50 copies/mL at Week 48
Status: Recruiting Start Date: February 2013 Completion Date: September 2015
20120230: Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease on Hemodialysis
This study is designed to assess the efficacy and safety of AMG 416 compared with placebo in the treatment of SHPT in CKD subjects receiving hemodialysis as assessed by the change from baseline in serum iPTH, cCa x P and phosphorus.
Status: Recruiting Start Date: March 2013 Completion Date: May 2014
Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation
The purpose of this research study is to find out if the drug Bortezomib (VELCADE ®), along with a procedure called plasmapheresis, can be effective at desensitization. Bortezomib works is by decreasing plasma cells in the blood. Plasma cells produce [more...]  antibodies. Plasmapheresis is a procedure that removes antibodies from the blood. Plasma cells and the antibodies they produce can be involved in rejection after organ transplantation. This trial is trying to see if decreasing plasma cells and antibodies with Bortezomib and plasmapheresis can reduce complications while participants are waiting for their transplant and improve heart transplantation outcomes.
Status: Recruiting Start Date: May 2013 Completion Date: September 2017
Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).
Status: Recruiting Start Date: January 2013 Completion Date: April 2014
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Two-arm, randomized, prospective, open-label, multi-center, phase III study to compare the efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3 weeks) in patients with advanced (Stage IIIC) unresectable or metastatic (Stage IV) NRAS Q61 [more...]  mutation-positive melanoma. The mutation analysis will be performed at a central laboratory. Only those patients with Q61 mutation per central laboratory and meet all eligibility criteria will be randomized. A total of 393 patients will be randomized 2:1 to receive either MEK162 or dacarbazine. Patients will be stratified according to AJCC stage (IIIC, IVM1a, and IVM1b versus IVM1c), ECOG Performance status (0 versus 1) and prior first-line therapy (Ipilimumab-immunotherapies versus none). This study will use an Interactive Response Technology (IRT). The primary end point of the study is progression-free survival. Key secondary end point is overall survival
Status: Recruiting Start Date: July 2013 Completion Date: May 2016
Durolane Versus Phosphate Buffered Saline (PBS) in Knee Osteoarthritis
The purpose of the study is to determine whether a single intra-articular injection of Durolane is superior to a single injection of PBS for the relief of joint pain in patients with osteoarthritis of the knee.
Status: Recruiting Start Date: December 2012 Completion Date: 
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate Alzheimer's Disease.
Status: Recruiting Start Date: March 2013 Completion Date: January 2015
MAESTRO (Macitentan in Eisenmenger Syndrome To Restore Exercise Capacity)
Clinical study to assess the efficacy, safety, and tolerability of macitentan in subjects with Eisenmenger Syndrome.
Status: Recruiting Start Date: May 2013 Completion Date: June 2014
A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer
The study is designed to compare the clinical benefit following treatment with letrozole in combination with PD-0332991 versus letrozole in combination with placebo in postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer [more...]  therapies for their advanced/metastatic disease.
Status: Recruiting Start Date: February 2013 Completion Date: March 2016
A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease
The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.
Status: Recruiting Start Date: December 2012 Completion Date: October 2015
[1] 2 3 4 Next >>


Clinical trials allow volunteers access to medical treatment options before they are available to the general public. Participants often receive the best healthcare available for their condition.

Risks are a reality, however, and may include more frequent doctor visits, health risks (possibly life-threatening), and/or the treatment being ineffective. Trials are federally regulated with strict guidelines to protect participants.

Beverly Hills California Clinical Trials Information presented on is not intended to be a substitute for qualified medical advice visit or treatment with a real physician. We are not physicians. Always consult with a medical doctor (MD). is a website dedicated to listing clinical research studies in human subjects, including those specifically related to Beverly Hills California. Clinical research trials and medical trials take place in hundreds of cities across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectiveness of new treatments and drugs. The purpose of the studies is to answer specific human health questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions. Clinical trials allow volunteers access to medical treatment options before they are available to the general public. Many times the participants receive treatment for free, and sometimes they are paid for their time. Participants often receive the best healthcare available possible for their condition. Risks are a reality, however, and may include more frequent doctor visits, health risks (possibly life-threatening), and/or the treatment being ineffective. U.S. - based Beverly Hills California studies are federally regulated with strict guidelines to protect patients.

Latest Clinical
Trials News
Diabetes Clinical Trials search for new treatments and cures

There are a number of clinical trials underway to find effective treatments for diabetes, including new drugs, surgery and even transplantation.

Feeling Depressed? A clinical trial might help.

There are several current and ongoing trials of interventions for major depressive disorder, which is characterized by a disabling combination of symptoms causing severe disruption to the sufferer's ability to carry out routine functions and tasks of daily life.

The State of Constipation Clinical Trials

Constipation is a illness where the bowels cannot move waste material out of the body in a normal manner. There are various clinical trials recruiting participants to study the effectiveness of various treatments.

view more...